AHNAK2 and nonpapillary renal cell carcinoma: In recent years, many studies have reported that AHNAK2 could be a biomarker for the diagnosis and prognosis of PDAC, ccRCC, thymic carcinogenesis, bladder cancer, gastric cancer, and UM [11–18].